Evidence map›Paper›PMID 29939187›Full record

ArticleJournal of visualized experiments : JoVE2018

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish.

Xiao Ma, Yonghe Ding, Yong Wang, Xiaolei Xu

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Emerging Light-Sheet Fluorescence Microscopy for Cardiac Vascular Imaging in Zebrafish.Current treatment options in cardiovascular medicine · 2026
    Review
  5. Article
  6. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update.Journal of cardiovascular development and disease · 2025
    Review
  7. Review
  8. Article
  9. Bioreactor-grown exo- and endo-β-glucan from MalaysianFrontiers in bioengineering and biotechnology · 2022
    Article
  10. Article
  11. Circulation research · 2021
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiao MaClinical and Translational Sciences Track, Mayo Clinic Graduate School of Biomedical Sciences; Department of Biochemistry and Molecular Biology, Mayo Clinic; Division of Cardiovascular Diseases, Mayo Clinic.
Yonghe DingDepartment of Biochemistry and Molecular Biology, Mayo Clinic; Division of Cardiovascular Diseases, Mayo Clinic.
Yong WangDepartment of Biochemistry and Molecular Biology, Mayo Clinic; Division of Cardiovascular Diseases, Mayo Clinic; Institute of Life Science, Beijing University of Chinese Medicine.
Xiaolei XuClinical and Translational Sciences Track, Mayo Clinic Graduate School of Biomedical Sciences; Department of Biochemistry and Molecular Biology, Mayo Clinic; Division of Cardiovascular Diseases, Mayo Clinic; xu.xiaolei@mayo.edu.

Funding

Systematic Vertebrate Functional GenomicsR01GM063904 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI EKKER, STEPHEN CARL · 2001 to 2025
$10.7M
Genetic Studies of Sarcomere-based Cardiac Diseases (Diversity Supplement)R01HL081753 · NHLBI · MAYO CLINIC ROCHESTER · PI XU, XIAOLEI · 2005 to 2025
$7.8M
Epicardial remodeling in cardiomyopathy and cardiac agingR01HL107304 · NHLBI · MAYO CLINIC ROCHESTER · PI Xiaolei Xu · 2011 to 2026
$6.6M
Electronica Impedance to Access Metabolically Active PlaqueR01HL118650 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K · 2014 to 2022
$3.3M
Micro-Sensors to Study Electrical and Mechanical Coupling of Injured MyocardiumR01HL111437 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HSIAI, TZUNG K, XU, XIAOLEI · 2012 to 2020
$3.1M
NHLBI NIH HHS R01 HL081753NHLBI NIH HHS R01 HL107304NHLBI NIH HHS R01 HL111437NHLBI NIH HHS R01 HL118650NIGMS NIH HHS R01 GM063904
6 · The paper itself

Abstract

The genetically accessible adult zebrafish (Danio rerio) has been increasingly used as a vertebrate model for understanding human diseases such as cardiomyopathy. Because of its convenience and amenability to high throughput genetic manipulations, the generation of acquired cardiomyopathy models, such as the doxorubicin-induced cardiomyopathy (DIC) model in adult zebrafish, is opening the doors to new research avenues, including discovering cardiomyopathy modifiers via forward genetic screening. Different from the embryonic zebrafish DIC model, both initial acute and later chronic phases of cardiomyopathy can be determined in the adult zebrafish DIC model, enabling the study of stage-dependent signaling mechanisms and therapeutic strategies. However, variable results can be obtained with the current model, even in the hands of experienced investigators. To facilitate future implementation of the DIC model, we present a detailed protocol on how to generate this DIC model in adult zebrafish and describe two alternative ways of intraperitoneal (IP) injection. We further discuss options on how to reduce variations to obtain reliable results and provide suggestions on how to appropriately interpret the results.

Indexed as

AnimalsCardiomyopathiesDisease Models, AnimalDoxorubicinHumansZebrafishDoxorubicin

Identifiers

PMID29939187
PMCPMC6101627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.